Binding Site
Sector/industry
Clinical laboratory diagnostics
Binding Site is a Specialist Protein company committed to the
research, development, manufacture and distribution of innovative
immunodiagnostic assays for the global laboratory market. With
extensive expertise in antibody specificity technology, Binding
Site gives clinicians and laboratory staff the tools to
significantly improve diagnosis and management of patients across a
range of cancers and immune system disorders.
Both blood test kits and analysers are supplied into the two
main areas of the business, B cell dyscrasias and Detection of
immunodeficiency.
Origins date back to a group of researchers within Birmingham
University, UK who first started looking at innovative ways of
producing antibodies in the early 1970s. A private company was
founded to take the research forward and utilise any potential
commercial benefits
The UK head office houses all product development,
manufacturing, global distribution and marketing. Worldwide
customer support is also provided by a further 7 offices in the US
and Europe.
Management:
- Charles de Rohan, CEO
- Mark Culwick, CFO
Board of Directors:
- Kristoffer Melinder, Chairman
- Jonas Agnblad
- Jo Bradwell
- Hugh Carr-Smith
- Paul Hökfelt
- Javed Kahn
- Heino von Prondzynski
- Charles de Rohan
- Tommi Unkuri
Key Information:
Revenues 2010*:
EUR 49 million
Employees:
530
Ownership:
Nordic Capital Fund VII, controlling shareholding
Date of investment:
2011
Head office:
Birmingham, UK
* 2010 sales for companies still in portfolio; sales at exit for divested companies
